USADA announced today that Grace Bowlby, of Edina, Minn., an athlete in the sport of ice hockey, has accepted a public warning for failing to obtain a Therapeutic Use Exemption (TUE) prior to her use of an otherwise prohibited medication. Bowlby’s violation resulted from her use of spironolactone, a topical prescription medication, which she used under the care of a dermatologist for a diagnosed medical condition.

Bowlby, 23, declared the use of her medication on her doping control form at the time of sample collection and subsequently obtained a TUE through the established process under international rules authorizing future use of this medication in sport. Because Bowlby’s positive sample from September 2, 2021 was collected out of competition, there are no competitive results to disqualify.

• This media release was published by the US Anti-Doping Agency (USADA) on 16 December 2021. Click here for the original.